Transfer of Exosomal MicroRNAs Confers Doxorubicin Resistance in Osteosarcoma Cells

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2023 Mar 3

PMID 36866739

Authors

Tao Cai

Chunlin Zhang

Taichen Zhan

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the commonest primary malignant bone tumor in children and adolescents. However, chemotherapy resistance is a major challenge for the treatment of OS. Exosomes have been reported to serve an increasingly important role in different stages of tumor progression and chemotherapy resistance. The present study investigated whether exosomes derived from doxorubicin‑resistant OS cells (MG63/DXR) could be taken up in doxorubicin‑sensitive OS cells (MG63) and induce a doxorubicin‑resistant phenotype. MDR‑1, as the specific mRNA of chemoresistance, can be transferred by exosomes from MG63/DXR cells to MG63 cells. In addition, the present study identified 2,864 differentially expressed miRNAs (456 upregulated and 98 downregulated with fold‑change >2.0, P<5x10, and FDR<0.05) in all three sets of exosomes from MG63/DXR cells and MG63 cells. The related miRNAs and pathways of exosomes involved in the doxorubicin resistance were identified by bioinformatic analysis. A total of 10 randomly selected exosomal miRNAs were dysregulated in exosomes from MG63/DXR cells relative to MG63 cells by reverse transcription‑quantitative PCR detection. As a result, miR‑143‑3p was found high expressed in exosomes from doxorubicin‑resistant OS cells compared with doxorubicin‑sensitive OS cells and upregulation of exosomal miR‑143‑3p abundance associated with the poor chemotherapeutic response to OS cells. Briefly, transfer of exosomal miR‑143‑3p confers doxorubicin resistance in osteosarcoma cells.

Citing Articles

Role of non-coding RNA in exosomes for the diagnosis and treatment of osteosarcoma.

Liu X, Wang Y, Wang C, Wang X, Tang G, Xiong Z Front Oncol. 2024; 14:1469833.

PMID: 39512768 PMC: 11540661. DOI: 10.3389/fonc.2024.1469833.

Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research.

Chen L, He L, Liu B, Zhou Y, Lv L, Wang Z Front Oncol. 2024; 14:1255061.

PMID: 38532928 PMC: 10964489. DOI: 10.3389/fonc.2024.1255061.

E2F1 mediates competition, proliferation and response to cisplatin in cohabitating resistant and sensitive ovarian cancer cells.

Valdivia A, Cowan M, Cardenas H, Isac A, Zhao G, Huang H Front Oncol. 2024; 14:1304691.

PMID: 38344207 PMC: 10853425. DOI: 10.3389/fonc.2024.1304691.

Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?.

Bucci-Munoz M, Gola A, Rigalli J, Ceballos M, Ruiz M Life (Basel). 2023; 13(8).

PMID: 37629489 PMC: 10455762. DOI: 10.3390/life13081633.

References

Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T . Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018; 37(1):52. PMC: 5846230. DOI: 10.1186/s13046-018-0677-7. View

Zhao L, Liu W, Xiao J, Cao B . The role of exosomes and "exosomal shuttle microRNA" in tumorigenesis and drug resistance. Cancer Lett. 2014; 356(2 Pt B):339-46. DOI: 10.1016/j.canlet.2014.10.027. View

Wang H, Li Q, Niu X, Wang G, Zheng S, Fu G . miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncol Lett. 2017; 13(1):435-440. PMC: 5245146. DOI: 10.3892/ol.2016.5388. View

Santos J, da Silva Lima N, Sarian L, Matheu A, Ribeiro M, Derchain S . Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep. 2018; 8(1):829. PMC: 5770414. DOI: 10.1038/s41598-018-19339-5. View

Yu D, Wu Y, Zhang X, Lv M, Chen W, Chen X . Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222. Tumour Biol. 2015; 37(3):3227-35. DOI: 10.1007/s13277-015-4161-0. View

Li D, Hu J, Song H, Xu H, Wu C, Zhao B . miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. Am J Transl Res. 2017; 9(5):2276-2285. PMC: 5446510. View

Safaei R, Larson B, Cheng T, Gibson M, Otani S, Naerdemann W . Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005; 4(10):1595-604. DOI: 10.1158/1535-7163.MCT-05-0102. View

Gianferante D, Mirabello L, Savage S . Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017; 13(8):480-491. DOI: 10.1038/nrendo.2017.16. View

Wang L, He J, Xu H, Xu L, Li N . MiR-143 targets CTGF and exerts tumor-suppressing functions in epithelial ovarian cancer. Am J Transl Res. 2016; 8(6):2716-26. PMC: 4931165. View

10.

Nair R, Santos L, Awasthi S, von Erlach T, Chow L, Bertazzo S . Extracellular vesicles derived from preosteoblasts influence embryonic stem cell differentiation. Stem Cells Dev. 2014; 23(14):1625-35. DOI: 10.1089/scd.2013.0633. View

11.

Chen L, Yao H, Wang K, Liu X . Long Non-Coding RNA MALAT1 Regulates ZEB1 Expression by Sponging miR-143-3p and Promotes Hepatocellular Carcinoma Progression. J Cell Biochem. 2017; 118(12):4836-4843. DOI: 10.1002/jcb.26158. View

12.

Miller R . Contrasting epidemiology of childhood osteosarcoma, Ewing's tumor, and rhabdomyosarcoma. Natl Cancer Inst Monogr. 1981; (56):9-15. View

13.

Sun X, Dai G, Yu L, Hu Q, Chen J, Guo W . miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep. 2018; 8(1):606. PMC: 5766605. DOI: 10.1038/s41598-017-18739-3. View

14.

Provisor A, Ettinger L, Nachman J, Krailo M, Makley J, Yunis E . Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15(1):76-84. DOI: 10.1200/JCO.1997.15.1.76. View

15.

Robbins P, Morelli A . Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14(3):195-208. PMC: 4350779. DOI: 10.1038/nri3622. View

16.

Wei F, Ma C, Zhou T, Dong X, Luo Q, Geng L . Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. Mol Cancer. 2017; 16(1):132. PMC: 5526308. DOI: 10.1186/s12943-017-0694-8. View

17.

Corcoran C, Rani S, ODriscoll L . miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014; 74(13):1320-34. DOI: 10.1002/pros.22848. View

18.

Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji M . Exosome mediated communication within the tumor microenvironment. J Control Release. 2015; 219:278-294. DOI: 10.1016/j.jconrel.2015.06.029. View

19.

Lv M, Zhu X, Chen W, Zhong S, Hu Q, Ma T . Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 2014; 35(11):10773-9. DOI: 10.1007/s13277-014-2377-z. View

20.

Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M . Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One. 2014; 9(2):e88193. PMC: 3916404. DOI: 10.1371/journal.pone.0088193. View